¶ 1st Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions
The 1st Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions was a meeting held by the World Health Organization (WHO) on March 29, 2021.[1]
The event was followed by the 2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions on June 10, 2021.[2]
¶ Participants
| Name | Affiliation | Topic |
|---|---|---|
| Michael Ryan | World Health Organization | Opening remarks |
| Sylvie Briand | World Health Organization | WHO framework for monitoring & assessing SARS-CoV-2 variants |
| Session 1: Focus on SARS-CoV-2 Variants | ||
| Maria Van Kerkhovea | World Health Organization | Moderator |
| Boris Pavlin | World Health Organization | Epi update on SARS-CoV-2 variants of concern |
| Frank Konings | World Health Organization | Status of assessment of mutations, VOI and VOC in terms of understanding transmissibility, severity and potential impact on countermeasures |
| Volker Thiel | University of Bern | How WHO assesses knowledge and knowledge gaps and develops advice and guidance |
| Janet Diaz | World Health Organization | - |
| April Baller | World Health Organization | - |
| Session 2: Framework of Evidence for the SARS-CoV-2 Variants | ||
| Wenqing Zhang | World Health Organization | Moderator |
| John McCauley | Francis Crick Institute | Experience from influenza: vaccine virus selection system and risk assessment framework |
| Richard Webby | St. Jude Children's Research Hospital | Experience from influenza: vaccine virus selection system and risk assessment framework |
| Ana Maria Henao Restrepo | R&D Blueprint, World Health Organization | Moderator |
| Philip Krause | Food and Drug Administration (FDA) | Building a framework of evidence for the monitoring and assessment of vaccines in the context of SARS-CoV-2 variants |
| Kanta Subbarao | Peter Doherty Institute for Infection and Immunity | Moderator |
| Jakob Cramer | Coalition for Epidemic Preparedness Innovations (CEPI) | Structured Debate introduced by Ana Maria Henao Restrepo |
| Paul Fine | London School of Hygiene and Tropical Medicine | Structured Debate introduced by Ana Maria Henao Restrepo |
| Thomas Fleming | University of Washington | Structured Debate introduced by Ana Maria Henao Restrepo |
| Alan Khoo | International Medical University | Structured Debate introduced by Ana Maria Henao Restrepo |
| Ira Longini | University of Florida | Structured Debate introduced by Ana Maria Henao Restrepo |
| Cesar Muñoz-Fontela | R&D Blueprint, World Health Organization | Structured Debate introduced by Ana Maria Henao Restrepo |
| Richard Neher | University of Basel | Structured Debate introduced by Ana Maria Henao Restrepo |
| Jerome Singh | University of KwaZulu-Natal | Structured Debate introduced by Ana Maria Henao Restrepo |
| David Wentworth | Centers for Disease Control and Prevention (CDC) | Structured Debate introduced by Ana Maria Henao Restrepo |
| Session 3: Impact on Public Health Decision-Making | ||
| Katherine O'Brien | World Health Organization | Moderator |
| Soumya Swaminathan | World Health Organization | Interplay between vaccine supply, vaccine performance, and emergence of SARS-CoV-2 variants |
| Sarah Cobey | University of Chicago | Interplay between vaccine supply, vaccine performance, and emergence of SARS-CoV-2 variants |
| Annelies Wilder-Smith | World Health Organization | Interplay between vaccine supply, vaccine performance, and emergence of SARS-CoV-2 variants |
| Rogerio Gaspar | World Health Organization | Moderator |
| Philip Krause | Food and Drug Administration (FDA) | Perspectives from regulators and developers |
| Adam Hacker | Coalition for Epidemic Preparedness Innovations (CEPI) | Perspectives from regulators and developers |
| Boitumelo Semete | South African Health Products Regulatory Authority (SAHPRA) | Perspectives from regulators and developers |
| V.G. Somani | Central Drugs Standard Control Organisation (CDSCO) | Perspectives from regulators and developers |
| David Heymann | Strategic and Technical Advisory Group on Infectious Hazards with Pandemic and Epidemic Potential (STAG-IH) | Impact on public health decision-making |
| Alejandro Cravioto | Strategic Advisory Group of Experts on Immunization (SAGE) | Impact on public health decision-making |
Global Consultation on a Decision Framework for Assessing the Impact of SARS-CoV-2 Variants of Concern on Public Health Interventions. (2021, March 29). World Health Organization. https://web.archive.org/web/20230311214713/https://www.who.int/publications/m/item/global-consultation-on-a-decision-framework-for-assessing-the-impact-of-sars-cov-2-variants-of-concern-on-public-health-interventions ↩︎
2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions. (2021). World Health Organization. https://web.archive.org/web/20230312032446/https://www.who.int/docs/default-source/coronaviruse/report-sars-global-consultation_10june2021.pdf ↩︎